CDKN1C and glioma: Furthermore, miR-25 has been shown to increase glioma cell proliferation by directly targeting the CDK inhibitor type 1C (CDKN1C or p57) resulting in an increase of S/M phase cells and a decrease of G0/G1 phase cells [62] (Table 3) (Figure 3).